NCT03557359 2025-11-03
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
Phase 2 Completed
Clinical Trials
8 trialsNCT04056910 2025-02-27
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
University of Pittsburgh
Phase 2 Completed
NCT02960230 2025-01-22
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
University of California, San Francisco
Phase 1/2 Completed
NCT04267146 2024-12-02
NIVOGLIO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT03925246 2024-04-02
REVOLUMAB
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT02829931 2023-01-19
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02526017 2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT02529072 2020-03-26
AVERT
Duke University
Phase 1 Completed